197 related articles for article (PubMed ID: 21536234)
1. Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.
Chandra HS; Heisterkamp NC; Hungerford A; Morrissette JJ; Nowell PC; Rowley JD; Testa JR
Cancer Genet; 2011 Apr; 204(4):171-9. PubMed ID: 21536234
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal abnormalities in Ph- cells of patients on imatinib.
McMullin MF; Humphreys M; Byrne J; Russell NH; Cuthbert RJ; O'Dwyer ME
Blood; 2003 Oct; 102(7):2700-1; author reply 2701. PubMed ID: 14504073
[No Abstract] [Full Text] [Related]
3. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Ostro D; Cheung K; Kamel-Reid S; Lipton JH
Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
[No Abstract] [Full Text] [Related]
4. Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
Okada M; Satake A; Kaida K; Taniguchi K; Yoshihara S; Ikegame K; Tamaki H; Soma T; Fujimori Y; Ogawa H
Int J Hematol; 2011 Feb; 93(2):243-246. PubMed ID: 21279819
[TBL] [Abstract][Full Text] [Related]
5. The Philadelphia chromosome: celebration of the 50th anniversary of its discovery.
Knutsen T
J Assoc Genet Technol; 2011; 37(1):5-10. PubMed ID: 21430353
[TBL] [Abstract][Full Text] [Related]
6. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N
Leuk Res; 2009 Dec; 33(12):e218-20. PubMed ID: 19525008
[No Abstract] [Full Text] [Related]
7. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
[TBL] [Abstract][Full Text] [Related]
8. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
Zaccaria A; Valenti AM; Donti E; Gozzetti A; Ronconi S; Spedicato F
Haematologica; 2007 Apr; 92(4):564-5. PubMed ID: 17488671
[TBL] [Abstract][Full Text] [Related]
9. [Leukemia: A highly malignant disease].
Marschalek R; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2012 May; 41(3):186-9. PubMed ID: 22844664
[No Abstract] [Full Text] [Related]
10. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
[No Abstract] [Full Text] [Related]
11. Translation of the Philadelphia chromosome into therapy for CML.
Druker BJ
Blood; 2008 Dec; 112(13):4808-17. PubMed ID: 19064740
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
13. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targeting therapy for chronic myeloid leukemia].
Kimura S
Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
[No Abstract] [Full Text] [Related]
15. Janet Rowley (1925-2013).
Druker BJ
Nature; 2014 Jan; 505(7484):484. PubMed ID: 24451535
[No Abstract] [Full Text] [Related]
16. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Herens C; Baron F; Croisiau C; Tassin F; Bours V
Cancer Genet Cytogenet; 2003 Nov; 147(1):78-80. PubMed ID: 14580776
[TBL] [Abstract][Full Text] [Related]
17. The legacy of the Philadelphia chromosome.
Koretzky GA
J Clin Invest; 2007 Aug; 117(8):2030-2. PubMed ID: 17671635
[TBL] [Abstract][Full Text] [Related]
18. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
19. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
20. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
